The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms in patients with chronic heArt faiLure) trials evaluated the effect of 10 mg empagliflozin versus placebo on exercise ability in patients with heart failure. EMPERIAL-Reduced (NCT03448419) randomized 312 patients with heart failure with reduced ejection fraction (LVEF ≤ 40%) to receive either … [Read more...] about Effect of Empagliflozin on exercise ability and symptoms in heart failure patients
Cardiology research news
Renin-angiotensin system inhibitors improve transcatheter aortic valve replacement prognosis
Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to replace narrowed aortic valves that fail to properly open. Following this procedure, however, left ventricular (LV) hypertrophy and myocardial fibrosis persist and are linked to worse prognosis. Renin-angiotensin system (RAS) inhibition can protect against these risks and in response to … [Read more...] about Renin-angiotensin system inhibitors improve transcatheter aortic valve replacement prognosis
Superior Cardiac Outcomes with addition of SGLT2i to GLP-1RA
Atherosclerotic cardiovascular disease and heart failure occur more frequently in patients with type 2 diabetes mellitus. Therefore, the major goal of care of patients with type 2 diabetes is to reduce the incidence of these events. Both glucagon-like peptide agonists (GLP-1RA’s) and sodium-glucose co-transporter 2 inhibitors (SGLT2i’s) can independently improve glucose control … [Read more...] about Superior Cardiac Outcomes with addition of SGLT2i to GLP-1RA
SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include elevated hepatic or muscular enzymes, neurological symptoms, and muscular symptoms collectively referred to as statin-associated muscle symptoms (SAMS).1 SAMS seems to occur less frequently in randomized control trials than in observational studies. These results suggest that … [Read more...] about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
Top 10 Highlights of AHA 2020 Congress
The American Heart Association (AHA) 2020 congress took place virtually this year, from November 13 to 17, 2020. Here is our curated list of the top scientific sessions from AHA 2020. SOLOIST-WHF trial1: Sotagliflozin superior to placebo in preventing deaths and hospitalizations in patients with type 2 diabetes and worsening heart failure. This multicenter, double-blind … [Read more...] about Top 10 Highlights of AHA 2020 Congress